SCHEMBL2274136

SCHEMBL2274136

O=C(CCl)Nc1ccc2c(c1NC(=O)CSc1ccccc1)C(=O)c1ccccc1C2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.51
MAPT P10636 3/20 0.51
HTT P42858 2/20 0.51
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 3/20 0.46
APEX1 P27695 1/20 0.45
ALDH1A1 P00352 5/20 0.43
BLM P54132 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TSHR P16473 1/20 0.42
THRB P10828 1/20 0.42
MAPK1 P28482 4/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PKM P14618 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MMP14 P50281 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12393966 0.88 SMN1; SMN2 (0.47) MAPTMEN1KMT2AALDH1A1BLM
SCHEMBL2269177 0.83 CASP3 (0.48) MAPTMEN1KMT2AALDH1A1BLM
SCHEMBL2267954 0.82 TERT (0.47) MAPTMEN1KMT2AALDH1A1BLM
SCHEMBL6366249 0.82 L3MBTL1 (0.65) L3MBTL1MAPTHTTMEN1KMT2A
SCHEMBL2272366 0.81 CYP1A2 (0.51) MAPTHTTMEN1KMT2ALMNA
SCHEMBL13343841 0.81 L3MBTL1 (0.60) L3MBTL1MAPTHTTMEN1KMT2A
SCHEMBL2267203 0.81 TERT (0.45) MAPTMEN1KMT2AALDH1A1BLM
SCHEMBL2268733 0.80 NPC1 (0.49) L3MBTL1MAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL2274239 0.79 TERT (0.43) MAPTMEN1KMT2AALDH1A1BLM
SCHEMBL712444 0.78 TERT (0.50) MAPTMEN1KMT2AALDH1A1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US claimed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US claimed
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US disclosed
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US disclosed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US disclosed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US disclosed
US-8304415-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-11-06 US disclosed
US-8304415-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-11-06 US disclosed
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA1, ANXA5, ANXA2 L3MBTL1 4856/4885MAPT 4724/4885HTT 3976/4885
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA5, ANXA1, HCCS L3MBTL1 4870/4885MAPT 4820/4885HTT 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.